210 results on '"Jessen, Bart"'
Search Results
2. Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose
3. Abstract LB349: The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics
4. Figure S6 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
5. Data from Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
6. Supplemental Table 5 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
7. Supplemental Table 2 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
8. Supplemental Figure 2 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
9. Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
10. Data from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
11. Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
12. Supplementary Figure Legends from Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
13. Supplemental Figure 3 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
14. Supplementary Figures 1 - 5 from Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
15. Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
16. Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
17. A distal region of the human TGM1 promoter is required for expression in transgenic mice and cultured keratinocytes
18. Supplementary References from Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
19. Supplementary Figure Legends from Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
20. Supplemental Tables and Figures from Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
21. 1258 PBMC humanized mouse model with clinical relevance in assessing the safety profile of 4–1BB agonists utomilumab and urelumab
22. Validation of a clinically relevant humanized mouse model for the safety assessment of 4-1BB agonists utomilumab and urelumab.
23. The contribution of physicochemical properties to multiple in vitro cytotoxicity endpoints
24. Lysosome Dysfunction: An Emerging Mechanism of Xenobiotic-Induced Toxicity
25. Transient knock down of checkpoint kinase 1 in hematopoietic progenitors is linked to bone marrow toxicity
26. A high content screening assay for identifying lysosomotropic compounds
27. Cardiovascular differentiation of imatinib and bosutinib in the rat
28. Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells
29. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion
30. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact
31. Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
32. Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase
33. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature
34. Abstract 99: Phenotypic characterization of knockdown of CDKs in the intestinal epithelial cells
35. Phenotypic Characterization of Targeted Knockdown of Cyclin-Dependent Kinases in the Intestinal Epithelial Cells
36. Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E2 Agonist
37. Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells
38. The Relevance of a 3D Corneal Model in Assessing the Safety of the Topical Ocular Formulation Preservative Benzalkonium Chloride in Xalatan and Its Vehicle: Poster No.: GC-D2-147 Panel No.: 147
39. Retinal and Peripheral Nerve Toxicity Induced by the Administration of a Pan-Cyclin Dependent Kinase (cdk) Inhibitor in Mice
40. Gastric and Pancreatic Lesions in Rats Treated with a Pan-CDK Inhibitor
41. Assessment of Hepatocytes and Liver Slices as in Vitro Test Systems to Predict in Vivo Gene Expression
42. Role of Sp1 Response Element in Transcription of the Human Transglutaminase 1 Gene
43. Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
44. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model
45. Keratinocyte Differentiation Marker Suppression by Arsenic: Mediation by AP1 Response Elements and Antagonism by Tetradecanoylphorbol Acetate
46. Lysosomal adaptation: How cells respond to lysosomotropic compounds
47. Validation of Cross-Species Reactivity of the VEGF-A/PDGFRβ Bifunctional Antibody PF-06653157
48. Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
49. Abstract 1635: Mechanistic investigation of neutropenia associated with palbociclib
50. Contribution of Membrane Trafficking Perturbation to Retinal Toxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.